Shareholders of Gecina (ENXTPA:GFC) approved all resolutions at the latest Annual General Meeting, including a dividend and renewals to the board of directors. The AGM backed a targeted share buyback program aimed at managing the company’s capital structure and helping offset dilution. Gecina highlighted solid leasing activity and progress on its property portfolio, including new prime office leases and asset disposals aligned with its long term plans. Gecina’s share price stands at €72.25,...

If you are wondering whether Gecina is trading at an attractive price today, it helps to step back and ask what the current share price actually implies about the business. The stock closed at €76.80, with a 2.2% gain over the last 7 days, a roughly flat 30 day return of 0.3% decline and year to date and 1 year returns of 4.2% and 11.0% declines respectively, while the 3 and 5 year returns are 16.1% and 14.4% declines. Recent news coverage around European real estate has focused on how...

If you are wondering whether Gecina's current share price reflects its true worth, this article walks through what the numbers are actually saying about the stock. Gecina shares last closed at €82.80, with returns of 2.3% over 7 days, 4.6% over 30 days, 3.2% year to date, and a 1.2% decline over 1 year, which can change how investors think about both potential upside and risk. Recent coverage of Gecina has focused on its position in the French real estate sector and how its portfolio sits...

Gecina (ENXTPA:GFC) shares have caught investors' attention lately as the stock continues to move against the broader French real estate sector. Recent performance signals an interesting value story emerging and invites a closer look at its fundamentals. See our latest analysis for Gecina. While Gecina’s share price has slipped 9.1% year-to-date and 6.1% over the past quarter, recent moves seem to reflect shifting investor sentiment and ongoing sector pressures more than fundamental weakness...

Thinking about what to do with your GL Events shares? Whether you are sizing up an entry point or reassessing your position after a strong rally, now is a great time to take stock of what is really happening beneath the surface. GL Events is one of those names where, if you had blinked a year ago, you might have missed some serious upside. Over the past five years, the stock has delivered a remarkable 219.9% return, and it is up 103.9% over three years alone. Even with a recent pullback of...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.